Inhaled Salbutamol Versus Placebo for the Treatment of Acute IgE-Mediated Abdominal Pain From Allergic Food Reactions (INSPIRE Trial): A Double-Blind Randomized Trial.
J Allergy Clin Immunol PractJun 16, 2026 (epub)
Clinical ResearchAllergy & Immunology
Camille Braun, Eloïse Antony, Marie-Lee Simard et al.
✦ AI-curated · Sources linked
In 30 seconds
The INSPIRE trial evaluated inhaled salbutamol's efficacy in treating moderate-to-severe IgE-mediated abdominal pain in patients aged 6 to 55 years. This double-blind, randomized trial found that the median time to patient-perceived adequate analgesia was 6.0 minutes for salbutamol, while the placebo group did not reach this endpoint within 30 minutes (hazard ratio, 0.35; P = .034).
Key findings
- Median time to adequate analgesia was 6.0 minutes for salbutamol versus not reached for placebo.
- Median time to complete resolution of pain was 10.0 minutes with salbutamol versus not reached for placebo.
- Hazard ratio for adequate analgesia with salbutamol was 0.35 (95% CI, 0.12-0.99; P = .034).
- The trial was terminated early due to slower-than-expected recruitment.
Why it matters
This study suggests that inhaled salbutamol may provide rapid relief for patients experiencing acute abdominal pain due to IgE-mediated food allergies, addressing a significant gap in treatment options.
What to keep in mind
The trial was terminated early, which may limit the robustness of the findings.